CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gloucester Pharmaceuticals today announced the presentation of positive data from a Phase 2b registration trial of romidepsin in patients with advanced cutaneous T-cell lymphoma (CTCL). The results were presented at the International Investigative Dermatology (IID) meeting in Kyoto, Japan, May 14-17, 2008. Romidepsin is a novel, cyclic peptide, pan-HDAC inhibitor under investigation for hematologic malignancies.
